Ziltivekimab is one of 79 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
75 competitors in Acute Myocardial Infarction
Plavix
Bayer Aspirin
Radicava
Avapro
Praluent
Leqvio
Neoral
Onglyza
Zebeta
Angiomax
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details